Molbio Diagnostics shares made a strong debut on both NSE and BSE, listing at ₹980 against the issue price of ₹807 — a premium of 21.44%. The IPO received an overall subscription of 70.27 times, reflecting strong investor confidence in the company’s leadership in the molecular diagnostics space and its Truenat platform, which is deployed across 90+ countries.